傳遭凱雷減持閱文(00772.HK)市前有涉資近10億大手上板股價急挫近11%失50天線
傳遭股東減持閱文集團(00772.HK)市前有一宗2,800萬股每股35.5元(較昨天收市價折讓約5.6%)非自動對盤上板,涉資9.94億元。該股扭兩連升,今早一舉跌破50、100、10天及20天線(34.13-36.74元),最多急挫近13%低見32.8元,現造33.6元,急吐近11%,成交增至3,821萬股,涉資13.37億元。
外電昨天引述消息指,凱雷集團擬以每股35.5-36元,轉讓2,800萬股(或佔已發股本約2.7%)閱文股份,套最多逾10億元。資料顯示,截至去年底,凱雷投資工具Luxun Investment持有閱文4.86%股權,為公司第四大股東。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.